Daisho Microline Holdings Limited announced a series of senior‐level changes effective 20 April 2026.
Key changes 1. Resignations • Mr Wong Siu Hung, Patrick stepped down as Non-Executive Director and ceased to act as Authorised Representative under Listing Rule 3.05 to focus on other business commitments. • Mr Lee Man Kwong resigned as the company’s Process Agent in Hong Kong.
2. New appointments • Dr Sun Jingan, aged 52, joined the board as Executive Director and immediately assumed the roles of Authorised Representative and Process Agent. • Dr Sun holds a bachelor’s degree in investment economics (Shandong University of Finance and Economics), and master’s and doctoral degrees in finance (Renmin University of China). He is also a CFA charter-holder. • Professional experience spans 25 years across strategic planning, technology commercialisation and investment management, including senior posts at CITIC Capital entities, Value Partners Private Equity Fund and China Shipping Fund. In 2024 he founded Jsmart Technologies Limited, specialising in robotics and embodied AI.
3. Remuneration and tenure • Dr Sun has signed a three-year service contract, automatically extendable for successive one-year terms, with one month’s notice required for termination by either party. • Monthly director’s remuneration is fixed at HK$25,000, set by the board on remuneration committee recommendation.
4. Shareholding structure • Jsmart Technologies Limited, jointly owned by Dr Sun and his spouse Ms Ma Ying, holds 280.00 million Daisho Microline shares, representing approximately 17.36 % of issued capital. Under Hong Kong securities regulations, Dr Sun is deemed interested in this stake, classifying both Jsmart and Dr Sun as substantial shareholders.
Post-change board composition • Executive Directors: Lee Man Kwong (Chairman), Sun Jingan • Non-Executive Director: Yau Pak Yue • Independent Non-Executive Directors: Chan Yau Ching, Bob; Leung Hoi Ming; Lin Ying
The board expressed gratitude to Mr Wong for his service and formally welcomed Dr Sun to his new roles. All disclosures were made in accordance with Hong Kong Listing Rule 13.51(2).
Comments